AC
TEVA icon

Ascend Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Ascend Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-449,390
Closed -$8.52M – 269
2017
Q4 		$8.52M Buy
+449,390
New +$6.76M 0.32% 87
2016
Q1 		– Sell
-357,991
Closed -$23.5M – 147
2015
Q4 		$23.5M Buy
+357,991
New +$22.1M 0.83% 38
2015
Q3 		– Sell
-505,119
Closed -$29.9M – 167
2015
Q2 		$29.9M Buy
505,119
+102,269
+25% +$6.31M 0.98% 37
2015
Q1 		$25.1M Buy
+402,850
New +$23.4M 0.86% 37
2014
Q3 		– Sell
-125,515
Closed -$6.58M – 213
2014
Q2 		$6.58M Sell
125,515
-211,485
-63% -$10.8M 0.22% 117
2014
Q1 		$17.8M Sell
337,000
-1,638,045
-83% -$75.7M 0.46% 66
2013
Q4 		$79.2M Buy
+1,975,045
New +$77.8M 2.41% 5
2013
Q3 		– Sell
-43,696
Closed -$1.71M – 237
2013
Q2 		$1.71M Buy
+43,696
New +$1.7M 0.07% 152

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ascend Capital's TEVA Position: Q1 2018 in Review

Ascend Capital sold out of Teva Pharmaceuticals (TEVA) in Q1 2018, closing a stake of 449,390 shares — an estimated $8.52M sold.

Ascend Capital first reported a position in TEVA in Q2 2013 and held it in 8 quarters. The position peaked at $79.2M in Q4 2013. 506 funds tracked by Wall St. Rank hold TEVA as of Q1 2018.

  • Ascend Capital reported no remaining Teva Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Ascend Capital sold 449,390 Teva Pharmaceuticals shares in Q1 2018, an estimated $8.52M.
  • Ascend Capital first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 8 quarters.
  • Ascend Capital's Teva Pharmaceuticals position peaked at $79.2M in Q4 2013.
  • 506 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2018.

Based on Ascend Capital's 13F filing for Q1 2018, filed 14 May 2018.